Evidence map›Paper›PMID 38796525›Full record

ReviewJournal of ovarian research2024

Exosomes in diagnostic and therapeutic applications of ovarian cancer.

Dhaval Bhavsar, Rajeswari Raguraman, Dongin Kim, Xiaoyu Ren, Anupama Munshi, Kathleen Moore, Vassilios Sikavitsas, Rajagopal Ramesh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of ovarian research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dhaval Bhavsar *Department of Pathology, University of Oklahoma Health Sciences Center, 975 NE, 10th Street, Oklahoma City, OK, 73104, USA.
Rajeswari Raguraman *Department of Pathology, University of Oklahoma Health Sciences Center, 975 NE, 10th Street, Oklahoma City, OK, 73104, USA.
Dongin KimDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, 1110 N, Stonewall Ave, Oklahoma City, OK, 73104, USA.
Xiaoyu RenDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, 1110 N, Stonewall Ave, Oklahoma City, OK, 73104, USA.
Anupama MunshiDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, 975 NE, 10th Street, Oklahoma City, OK, 73104, USA.
Kathleen MooreDepartment of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, 800 NE, 10th Street, Oklahoma City, OK, 73104, USA.
Vassilios SikavitsasOU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 800 NE, 10th Street, Oklahoma City, OK, 73104, USA.
Rajagopal RameshDepartment of Pathology, University of Oklahoma Health Sciences Center, 975 NE, 10th Street, Oklahoma City, OK, 73104, USA. rajagopal-ramesh@ouhsc.edu.

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
Exosomes as carriers of cancer therapeuticsR01CA254192 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAMESH, RAJAGOPAL · 2021 to 2025
$2.8M
Engineered Nanoformulation for Immune-modulation in CancerR01CA282735 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Rajagopal Ramesh · 2023 to 2026
$2.2M
HuR Targeted Nanotherapy for Lung CancerR01CA167516 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAMESH, RAJAGOPAL · 2013 to 2017
$1.9M
An improved IL-24 gene-based therapeutic for cancerR01CA233201 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAMESH, RAJAGOPAL · 2019 to 2023
$1.7M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA167516NCI NIH HHS R01 CA233201NCI NIH HHS R01 CA254192NCI NIH HHS R01 CA282735NIH HHS P30CA225520NIH HHS R01 CA167516, R01 CA233201, R01 CA254192, R01 CA282735
6 · The paper itself

Abstract

Ovarian cancer accounts for more deaths than any other female reproductive tract cancer. The major reasons for the high mortality rates include delayed diagnoses and drug resistance. Hence, improved diagnostic and therapeutic options for ovarian cancer are a pressing need. Extracellular vesicles (EVs), that include exosomes provide hope in both diagnostic and therapeutic aspects. They are natural lipid nanovesicles secreted by all cell types and carry molecules that reflect the status of the parent cell. This facilitates their potential use as biomarkers for an early diagnosis. Additionally, EVs can be loaded with exogenous cargo, and have features such as high stability and favorable pharmacokinetic properties. This makes them ideal for tumor-targeted delivery of biological moieties. The International Society of Extracellular Vesicles (ISEV) based on the Minimal Information for Studies on Extracellular Vesicles (MISEV) recommends the usage of the term "small extracellular vesicles (sEVs)" that includes exosomes for particles that are 30-200 nm in size. However, majority of the studies reported in the literature and relevant to this review have used the term "exosomes". Therefore, this review will use the term "exosomes" interchangeably with sEVs for consistency with the literature and avoid confusion to the readers. This review, initially summarizes the different isolation and detection techniques developed to study ovarian cancer-derived exosomes and the potential use of these exosomes as biomarkers for the early diagnosis of this devastating disease. It addresses the role of exosome contents in the pathogenesis of ovarian cancer, discusses strategies to limit exosome-mediated ovarian cancer progression, and provides options to use exosomes for tumor-targeted therapy in ovarian cancer. Finally, it states future research directions and recommends essential research needed to successfully transition exosomes from the laboratory to the gynecologic-oncology clinic.

Indexed as

Biomarkers, TumorExosomesOvarian NeoplasmsFemaleHumansBiomarkers, TumorDiagnosticsDrug deliveryDrug resistanceExosomesExtracellular vesiclesGynecological cancersMetastasisOvarian cancerTumor microenvironment

Identifiers

PMID38796525
PMCPMC11127348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.